The contention that "the regulators will probably want to see a second pivotal Phase 3 study..." is not new information.
It has not been posted here or said by Ross once that even if this trial is successful it will automatically be granted the right to commercialisation. Please find evidence if otherwise, since you're doing such thorough research on Cynata.
You should pay attention, especially to detail.
I see we're back to talking about offices and how the FDA deems them crucial to trial approval. Good to know how your brain works (pic below for the MSB folks who can't read and need pictures to understand).
CYP Price at posting:
34.5¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)